93 related articles for article (PubMed ID: 23388130)
21. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
22. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
23. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
25. Neonatal mastocytosis with pachydermic bullous skin without c-Kit 816 mutation.
Walker T; von Komorowski G; Scheurlen W; Dorn-Beineke A; Back W; Bayerl C
Dermatology; 2006; 212(1):70-2. PubMed ID: 16319478
[TBL] [Abstract][Full Text] [Related]
26. Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis.
Ruano I; Gargini R; Izquierdo M
Br J Haematol; 2010 Jan; 148(1):59-68. PubMed ID: 19804454
[TBL] [Abstract][Full Text] [Related]
27. Mastocytosis - an update.
Amon U; Hartmann K; Horny HP; Nowak A
J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
[TBL] [Abstract][Full Text] [Related]
28. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
29. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant.
Wardelmann E; Neidt I; Bierhoff E; Speidel N; Manegold C; Fischer HP; Pfeifer U; Pietsch T
Mod Pathol; 2002 Feb; 15(2):125-36. PubMed ID: 11850541
[TBL] [Abstract][Full Text] [Related]
30. Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature.
Matsumoto NP; Yuan J; Wang J; Shen Q; Chen X; Kim Y; Zuppan CW; Chang CC; Cui W; Chen D; Shi M; Gisriel SD; Chen M; Xu ML; Pan Z
Mod Pathol; 2022 Jul; 35(7):865-874. PubMed ID: 35105959
[TBL] [Abstract][Full Text] [Related]
31. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.
Molderings GJ; Kolck UW; Scheurlen C; Brüss M; Homann J; Von Kügelgen I
Scand J Gastroenterol; 2007 Sep; 42(9):1045-53. PubMed ID: 17710669
[TBL] [Abstract][Full Text] [Related]
32. Mastozytose - Pathogenese, Klinik und Therapie.
Wagner N; Staubach P
J Dtsch Dermatol Ges; 2018 Jan; 16(1):42-59. PubMed ID: 29314684
[No Abstract] [Full Text] [Related]
33. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
Valent P; Sperr WR; Schwartz LB; Horny HP
J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
[TBL] [Abstract][Full Text] [Related]
34. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
35. Molecular pathology of c-kit proto-oncogene and development of gastrointestinal stromal tumors.
Kitamura Y; Hirota S; Nishida T
Ann Chir Gynaecol; 1998; 87(4):282-6. PubMed ID: 9891766
[No Abstract] [Full Text] [Related]
36. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of constitutive activation of c-kit receptor tyrosine kinase.
Tsujimura T; Kanakura Y; Kitamura Y
Leukemia; 1997 Apr; 11 Suppl 3():396-8. PubMed ID: 9209403
[TBL] [Abstract][Full Text] [Related]
38. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma.
Chott A; Guenther P; Huebner A; Selzer E; Parwaresch RM; Horny HP; Valent P
Am J Surg Pathol; 2003 Jul; 27(7):1013-9. PubMed ID: 12826896
[TBL] [Abstract][Full Text] [Related]
39. Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.
Dank G; Chien MB; London CA
Am J Vet Res; 2002 Aug; 63(8):1129-33. PubMed ID: 12171166
[TBL] [Abstract][Full Text] [Related]
40. A loss-of-function mutation of c-kit results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis.
Kitamura Y; Hirota S; Nishida T
Mutat Res; 2001 Jun; 477(1-2):165-71. PubMed ID: 11376697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
